New York City-based clinical-stage genetic medicine company advancing disease-modifying gene therapies for genetic cardiovascular conditions and genetic conditions of the central nervous system; in September 2026 it agreed to acquire Mantle Therapeutics to add Friedreich ataxia assets.
Close of the Mantle Therapeutics acquisition ($8.3M upfront)
Further LX2006 and LX2020 clinical data
Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million, aiming to expand its Friedreich’s ataxia (FA) portfolio while locking in three strategic collabo | Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.…
Chief Executive Officer
Chief Medical Officer
Chief Operating Officer